Amplicons are defective, helper-dependent herpes simplex virus type 1 (HSV-1)-based vectors able to convey more than 100 kbp of foreign DNA to the nucleus of mammalian cells. This unique feature make amplicons very appealing for preventive or therapeutic gene transfer requiring the transduction of very large pieces of DNA, as well as for upstream fundamental studies, such as functional genomics. Several recent achievements in amplicon technology have allowed to produce relatively large amounts of essentially helper-free amplicons, as well as to expand the host range of these vectors. In this review, we will update the current know-how concerning design, construction, and recent applications, as well as the potential and current limitations, of this interesting and promising class of vectors. Gene Therapy (2005) 12, S154-S158.
Introduction
Amplicon vectors 1 are HSV-1 particles identical to wildtype HSV-1 from the structural, immunological and hostrange points of view, but which carry a concatemeric form of a DNA plasmid, named the amplicon plasmid, instead of the viral genome. An amplicon plasmid is a standard Escherichia coli plasmid carrying one origin of replication (generally ori-S) and one packaging signal (pac or 'a') from HSV-1, in addition to the transgenic sequences of interest. The major interest of amplicons as gene transfer tools stems from the fact that they carry no virus genes and consequently do not induce synthesis of virus proteins. Therefore, these vectors are fully nontoxic for the infected cells and nonpathogenic for the inoculated organisms. A second and major advantage that arises from the lack of virus genes is that most of the 153 kbp capacity of the HSV-1 particle can be used to accommodate very large pieces of foreign DNA. This is undoubtedly the most outstanding property of amplicons, as there is no other viral vector system available displaying the capacity to deliver such a large amount of foreign DNA to the nuclear environment of mammalian cells. In addition to possessing a larger delivering capacity, amplicons can be considered as safer than defective recombinant HSV-1 vectors, as much as the absence of virus genes in the amplicon genome strongly reduces the risk of reactivation, complementation or recombination with latent HSV-1 genomes. Contrarily, high-titre amplicons are considerably more difficult to prepare in high amounts than recombinant-defective vectors.
The possibility of using amplicons to transduce large amounts of foreign DNA to both quiescent and dividing cells appeared however, and for a long-time, as an unattainable dream. Some major recent improvements in amplicon technology have now brought these potentialities into reality. These improvements are the development of production methods that generate significant amounts of nontoxic-amplicon vector stocks essentially free of contaminant helper particles, and the advent of DNA recombination techniques allowing to produce amplicon plasmids conveying more than 100 kbp of foreign DNA.
Generation of helper-free amplicon vectors
Classically, amplicon vectors were prepared in cells transfected with the amplicon plasmid and superinfected with helper HSV-1, which supplied the full set of proteins required to amplify and package the amplicon DNA into HSV-1 particles. Figure 1 shows pA-EUA1, a typical EGFP-expressing amplicon plasmid carrying a multiple cloning site for introducing any transgene of interest. As the helper virus used was generally a replication-defective mutant of HSV-1, the amplicon stocks were produced in transcomplementing cell lines. 2 However, the use of defective HSV-1 as helper resulted in the production of helper-contaminated vector stocks, and the contaminant helper particles, even if defective, induced significant cytotoxicity and inflammatory responses, 3 therefore preventing their use in gene therapy of vaccination protocols. To overcome these obstacles, different helper systems that produce essentially helperfree vector stocks have been recently developed. The first of these systems was based on the cotransfection of amplicon plasmids with a set of five overlapping cosmids that supplied the full-set of transacting HSV-1 functions required to build amplicon vectors. These cosmids however lacked the pac sequences, thus avoiding packaging of the helper virus genomes that could emerge following homologous recombination between the cosmids. 4 As a consequence, these cosmids allowed producing amplicon vectors with only very low levels of contamination with helper particles. This system was further improved by using a safer and more efficient bacterial artificial chromosome (BAC) as the source of HSV-1 functions, instead of the set of cosmids. 5 The HSV-1 helper genome carried by the BAC does not contain the viral packaging signals, it lacks at least one essential gene (encoding ICP27) and its size largely exceeds that of the wild-type HSV-1 genome. These helper genomes, therefore, cannot be packaged into newly assembled HSV-1 particles, and any eventual recombinant genome that could nevertheless arise in the vector stocks will be defective due to the absence of the gene encoding ICP27. 6 Although the more recent version of these systems does allow production of entirely helper-free amplicon stocks with titres exceeding 10 7 transducing units/ml, the total amount of amplicon vectors produced with this method is somewhat limited since it is based on DNA cotransfection procedures and the vector stocks produced in this way cannot be further amplified. Therefore, while this method is very well suited for producing amplicons for fundamental research or experimental gene transfer to small laboratory animals, it appears hardly suitable for large-scale production of amplicon vectors, as required for vaccination or gene therapy approaches.
A very different helper system recently developed is based on the deletion, by Cre/loxP site-specific recombination, of the packaging signals of the helper virus in the cells that are producing the amplicons. This system uses as helper a novel recombinant HSV-1 (named HSV-1 LaLdeltaJ) that carries a unique and ectopic packaging 'a' signal flanked by two loxP sites in parallel orientation. 7 This virus is Cre-sensitive and cannot be packaged in Cre-expressing cells, due to efficient deletion of the packaging signals. In addition, HSV-1 LaLdeltaJ lacks the two genes surrounding the virus packaging signals. One of these genes encodes the essential protein ICP4, while the other encodes the g34.5 protein. This helper virus is thus defective and can be produced only in ICP4 transcomplementing cells. The g34.5 protein is not essential in most cultured cells, but its absence renders the virus completely nonneurovirulent. Therefore, upon transfection of the amplicon plasmid to cells simultaneously expressing Cre and ICP4, infection with HSV-1 LaLdeltaJ helper virus will supply the required virus proteins to generate amplicon stocks. As most helper genomes will lose their packaging signals in these cells, the vector stocks will be only marginally contaminated (o0.2%) with helper particles, which are otherwise defective and nonpathogenic. Furthermore, since the Cre/loxP helper system is based on infection, instead of transfection procedures, it allows serial passages of the vector stocks, and a three-step protocol has been set-up that allows to prepare as much amplicons as required for a particular purpose. [7] [8] [9] Although this system is therefore well suited for large-scale production of amplicon vectors it needs further improvements as the presence of contaminant helper virus, even if marginal, could be a problem for some applications.
Infectious transfer of very large foreign DNA
Thanks to their ability to package very large transgenic sequences, amplicons can be used to deliver complete genomic DNA loci, or DNA sequences that regulate chromatin structure and function or subnuclear localization. This may prove useful to design improved gene therapy vectors having advantages such as prolonged, physiological and tissue-specific expression, generation of multiple splice variants from primary genomic transcripts, or synthesis of the full set of proteins required to assemble complex structures as well as metabolic or signalling pathways.
Almost the entire human genome is covered by fully sequenced BAC contigs that can be converted into amplicon plasmids by introducing one copy of HSV-1 ori-S and 'a' sequences, either by site-specific recombination or by homologous recombination in bacteria. This very important goal has been recently achieved by WadeMartins et al, 10 who used amplicons to transduce a 115 kbp insert containing the complete human hypoxanthine phosphoribosyl transferase (HPRT) locus into a human HPRT-deficient fibroblast cell line. The same team also used amplicons to deliver a 135 kbp fragment carrying the human low-density lipoprotein receptor (LDLR) into human fibroblasts derived from patients with familial hypercholesterolemia (FH). The infectious LDLR locus was shown to express at physiological levels in these cells. 11 Furthermore, the LDLR locus was maintained within a replicating episomal amplicon vector (carrying the Epstein-Barr virus (EBV) latent replicon, composed of EBNA-1 and ori-P sequences, see below) and expressed for 3 months at physiological levels following infectious delivery to CHO cells. 11 Still more recently, this group used amplicons to deliver a 132 kbp sequence of genomic DNA comprising the CDKN2A/CDKN2B region, and demonstrated that this locus was correctly expressed, allowing the synthesis of three cell-cycle regulatory proteins that are expressed from overlapping genes, utilizing alternative splicing and promoter usage. 12 These exciting experiments illustrate the outstanding potential of amplicons as genomic transfer vectors. 
HSV-1-based amplicon vectors AL Epstein
Expanding the amplicon host range
The studies described in the previous paragraphs were possible thanks to a third major achievement of amplicon technology: the possibility to avoid dilution of the episomic amplicon genomes in proliferating cells. As the amplicon genome does not express HSV-1 replication functions and does not integrate into the host chromosomes, it will be diluted upon cell proliferation. For this reason, amplicons were thought to be particularly well suited only for transduction into quiescent cells, like neurons, muscle cells or hepatocytes. However, it has been possible to construct amplicons that persist in proliferating cells, thanks to the introduction of ori-P and EBNA-1 genes from EBV, another member of the herpesvirus family, into the amplicon genome. 13 These EBV genetic elements, which ensure vegetative maintain and segregation of EBV latent genomes in human cells, also allow maintain and segregation of episomic amplicon genomes.
Applications
After the initial demonstration that they could be used to deliver foreign DNA, 14 23, 24 heat-shock proteins 25 or antioxidant enzymes, 26 in attempts to protect neurons against a variety of neurological insults. Amplicons have also been used to deliver tyrosine hydroxylase and other genes to the nigro-striatal system or to cultured striatal cells, in studies aimed to study or treat Parkinson's disease. 17, 27, 28 Finally, amplicons expressing genes affecting neurotransmitter action or neuroreceptor synthesis have been used to study behavioral traits like learning and memory. [29] [30] [31] [32] Other studies have shown that amplicons are also well suited for delivering genes to skeletal muscle myoblasts and myotubes, 33, 34 to cultured cardiomyocytes and heart slices, 35 to primary hepatocytes, 36 dendritic cells, 37 and many cell lines derived from human or murine cancers. In addition, the large transgenic capacity of amplicons has been exploited to efficiently transduce the full set of proteins of MoMLV retrovirus, thus rescuing integrated retrovirus vectors, 38-40 the nonstructural 41 or structural 42 proteins of hepatitis C virus (HCV), or the regulatory and coding sequences from adeno-associated virus (AAV) genome, in attempts to increase the stability of transduced genes by amplification or integration. 43 Lastly, amplicons have also been used as vaccines, for example against HIV 44 or intracellular bacteria (data not published). Taken together, these studies illustrate the broad potential of amplicons as gene transfer tools, able to efficiently deliver genes to many different target cells in a variety of experimental situations, in vitro and in vivo, both for fundamental studies, for vaccination protocols or for gene therapy trials. Figure 2 illustrates the transducing efficiency of amplicon vectors to cultured rat primary cardiomyocytes (a), rat primary hepatocytes (b), human glioma cells (c), as well as to rat hippocampal pyramidal neurons (d) in vivo.
Control of expression from amplicon vectors
Using helper-free vector stocks it is now possible to investigate how transgenic expression from amplicons is regulated in the absence of helper particles. Although the factors that control expression from the amplicon genome remain poorly understood, several teams, including ourselves, observed that parameters like the intensity, the length and the host range of transgene expression are remarkably different in helper-free and in helper-contaminated amplicon stocks. More precisely, using helperfree stocks, transgene expression becomes strikingly celltype, cell cycle and multiplicity of infection dependent. These restrictions, which have also been described with polydeleted recombinant vectors expressing no viral immediate-early proteins, 45 are usually not observed with helper-contaminated amplicons, indicating that both, cellular and viral functions, can modulate transgenic expression from the amplicon genome. A better understanding of the cellular and viral factors that contribute to the restrictions observed in transgenic expression from helper-free amplicon vectors will allow the positive modification of these vectors towards a highly improved and efficient gene therapy vector system.
Conclusion and perspectives
To summarize, thanks to the major achievements described in this review, it is becoming possible to efficiently use amplicons to transduce more than a 100 kbp of foreign DNA into quiescent or replicating cells, using nontoxic vectors that can now be produced to reasonable amounts. This is the current state of the art of amplicon vector technology. For the near future, three major areas of research can be anticipated in this field, the outcome of which will be critical to go beyond the current technological frontiers and applications. The first one relates to the possibility of scaling-up the production methods, thus producing still larger amounts of purified vectors than those generated by current procedures. The second major area relates, as mentioned in the preceding paragraph, to the possibility of controlling, improving, or achieving long-term physiological transgenic expression from amplicon vectors for therapeutic applications in different cell types. The third area, which is partially related to the previous one, concerns the possibility of avoiding transgenic silencing by the innate immune response. Although this area of research is emerging only now, it can be inferred from what is known about HSV-1 immune biology that amplicons will induce an antiviral cellular response, at least in some cell types, and will stimulate both the innate and adaptive branches of the immune response in the infected organism. These responses can result in the elimination of the vector or in the silencing of the therapeutic transgenes. More work should be done in order to better understand the vector/ host interactions, but it can be predicted that the large size capacity of the amplicon genome, allowing to express several viral or cellular proteins well known to downregulate or to inhibit the antiviral and immune responses, will be a major advantage of amplicons over other vectors to fight against the silencing cellular forces.
